ESR2
ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
Overview
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner. Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability.
CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Tamoxifen and Exemestane. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes clinical 0.98, affected pathway 0.61, literature 1.00, genetic association 0.54, animal model 0.51).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
- 1 · What it is
ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
- 2 · What goes wrong in cancer
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner.
- 3 · How drugs use it
No product in this corpus aims at ESR2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:3468 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92731 (protein name, function text, keywords and locations (REST API)); CIViC gene ESR2 (7 evidence items, 0 assertions, 3 variants; diseases: Breast Cancer, Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000140009 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: breast cancer 0.62 (GraphQL API, CC0))
Biology
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner. Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability. Location: Nucleus (UniProt). Locus 14q23.2-q23.3 (HGNC).
- Breast cancer: Open Targets association 0.62 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Prostate cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.98; CIViC holds 7 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ESR2" OR ABSTRACT:"ESR2" OR TITLE:"estrogen receptor 2" OR ABSTRACT:"estrogen receptor 2" OR TITLE:"Estrogen receptor beta" OR ABSTRACT:"Estrogen receptor beta" OR TITLE:"NR3A2" OR ABSTRACT:"NR3A2" OR TITLE:"Erb" OR ABSTRACT:"Erb" OR TITLE:"ER-beta" OR ABSTRACT:"ER-beta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ESR2, not a curated reading list.